دورية أكاديمية
Germline variation at 8q24 and prostate cancer risk in men of European ancestry
| العنوان: | Germline variation at 8q24 and prostate cancer risk in men of European ancestry |
|---|---|
| المؤلفون: | Matejcic, Marco, Saunders, Edward, J, Dadaev, Tokhir, Brook, Mark, N, Wang, Kan, Sheng, Xin, Olama, Ali, Amin Al, Schumacher, Fredrick, R, Ingles, Sue, A, Govindasami, Koveela, Benlloch, Sara, Berndt, Sonja, I, Albanes, Demetrius, Koutros, Stella, Muir, Kenneth, Stevens, Victoria, L, Gapstur, Susan, M, Tangen, Catherine, M, Batra, Jyotsna, Clements, Judith, Grönberg, Henrik, Pashayan, Nora, Schleutker, Johanna, Wolk, Alicja, West, Catharine, Mucci, Lorelei, Kraft, Peter, Cancel-Tassin, Geraldine, Sorensen, Karina, D, Maehle, Lovise, Grindedal, Eli, M, Strom, Sara, S, Neal, David, E, Hamdy, Freddie, C., Donovan, Jenny, Travis, Ruth, Hamilton, Robert, J, Rosenstein, Barry, Lu, Yong-Jie, Giles, Graham, G, Kibel, Adam, S, Vega, Ana, Bensen, Jeanette, T, Kogevinas, Manolis, Penney, Kathryn, L, Park, Jong, Bok, Stanford, Janet, L., Cybulski, Cezary, Nordestgaard, Børge, G., Brenner, Hermann, Maier, Christiane, Kim, Jeri, Teixeira, Manuel, R, Neuhausen, Susan, de Ruyck, Kim, Razack, Azad, Newcomb, Lisa, F, Lessel, Davor, Kaneva, Radka, Usmani, Nawaid, Claessens, Frank, Townsend, Paul, Dominguez, Manuela, G, Roobol, Monique, J, Menegaux, Florence, Khaw, Kay-Tee, Cannon-Albright, Lisa, A, Pandha, Hardev, Thibodeau, Stephen, N., Schaid, Daniel, J., Wiklund, Fredrik, Chanock, Stephen, Easton, Douglas, F., Eeles, Rosalind, Kote-Jarai, Zsofia, Conti, David, V, Haiman, Christopher |
| المساهمون: | Keck School of Medicine Los Angeles, University of Southern California (USC), The institute of cancer research London, Department of Clinical Neurosciences Cambridge, University of Cambridge UK (CAM), Centre for Cancer Genetic Epidemiology Cambridge, University of Cambridge UK (CAM)-Department of Oncology, Case Western Reserve University Cleveland, National Cancer Institute Bethesda (NCI-NIH), National Institutes of Health Bethesda, MD, USA (NIH), Warwick Medical School, University of Warwick Coventry, University of Manchester Manchester, Fred Hutchinson Cancer Research Center Seattle (FHCRC), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology Brisbane (QUT), Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet Stockholm, University College of London London (UCL), University of Turku, University of Tampere Finland, The Institute of Environmental Medicine Stockholm (IMM), Manchester Academic Health Science Centre (MAHSC), Harvard School of Public Health, Harvard T.H. Chan School of Public Health, Université Pierre et Marie Curie - Paris 6 (UPMC), Aarhus University Hospital, Aarhus University Aarhus, Oslo University Hospital Oslo, The University of Texas M.D. Anderson Cancer Center Houston, Addenbrooke's Hospital, Cambridge University NHS Trust, University of Oxford, School of Social and Community Medicine Bristol, University of Bristol Bristol, Icahn School of Medicine at Mount Sinai New York (MSSM), Centre for Molecular Oncology and Imaging, Centre for Molecular Oncology and Imaging, Barts Cancer Institute, Queen Mary University of London (QMUL), University of Melbourne, Brigham & Women’s Hospital Boston (BWH), Harvard Medical School Boston (HMS), CIBER de Enfermedades Raras (CIBERER), Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra Barcelona (UPF)-Catalunya ministerio de salud, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health (CIBERESP), IMIM-Hospital del Mar, Generalitat de Catalunya = Generalidad de Cataluña = Government of Catalonia, Universitat Pompeu Fabra Barcelona (UPF), University of Washington Seattle, German Cancer Research Center - Deutsches Krebsforschungszentrum Heidelberg (DKFZ), National Center for Tumor Diseases Dresden (NCT), Technische Universität Dresden = Dresden University of Technology (TU Dresden)-German Cancer Research Center - Deutsches Krebsforschungszentrum Heidelberg (DKFZ)-Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Universität Ulm - Ulm University Ulm, Allemagne, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto = University of Porto, Universiteit Gent = Ghent University (UGENT), University of Malaya = Universiti Malaya Kuala Lumpur, Malaisie (UM), Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf Hamburg (UKE), University of Alberta, Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven), University of California San Diego (UC San Diego), University of California (UC), Erasmus University Medical Center Rotterdam (Erasmus MC), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Saclay, School of Medicine University of Utah, Salt Lake City, University of Utah, University of Surrey (UNIS), Mayo Clinic Rochester, Royal Marsden NHS Foundation Trust |
| المصدر: | ISSN: 2041-1723. |
| بيانات النشر: | HAL CCSD Nature Publishing Group |
| سنة النشر: | 2018 |
| المجموعة: | Inserm: HAL (Institut national de la santé et de la recherche médicale) |
| مصطلحات موضوعية: | [SDV]Life Sciences [q-bio], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.GEN]Life Sciences [q-bio]/Genetics |
| الوصف: | International audience ; Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10−15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62–4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-01924689; https://hal.sorbonne-universite.fr/hal-01924689Test; https://hal.sorbonne-universite.fr/hal-01924689/documentTest; https://hal.sorbonne-universite.fr/hal-01924689/file/s41467-018-06863-1.pdfTest |
| DOI: | 10.1038/s41467-018-06863-1 |
| الإتاحة: | https://doi.org/10.1038/s41467-018-06863-1Test https://hal.sorbonne-universite.fr/hal-01924689Test https://hal.sorbonne-universite.fr/hal-01924689/documentTest https://hal.sorbonne-universite.fr/hal-01924689/file/s41467-018-06863-1.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.6C59EAF1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41467-018-06863-1 |
|---|